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have had time to conduct IRP against Norwegian prices yet, but also because the list 
prices remain unchanged, and IRP at the discount level remains rare.
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Objectives: Defibrotide had market authorization (MA) in treatment of severe 
veno-occlusive disease (VOD) and negative opinion for VOD prevention (October 
2013). Before, in France, defibrotide get in 2009 a compassionate use (temporary use 
authorization) in VOD treatment and prevention with a specific financing. Since 
the MA, the high cost of defibrotide remains a major problem for hospital budg-
ets. Assessment of economic impact of defibrotide treatment and perspectives to 
frame indications to reduce costs were purposed for the 37 hospitals of the Public 
Assistance–Hospitals of Paris. MethOds: Data collected were: i) consumptions/
expenditures in défibrotide from 2011 to 2014 and extrapolated values in 2015; ii) 
2014 medical information from PMSI hospital database (French medical information 
system program); iii) Diagnostic Related Group (DRG) tariff and part of drugs cost; 
iv) experts in hematology opinions. Results: Since 2011, consumptions increased 
to reach 15,750 vials for 5.2M€ in 2014. In contrast, extrapolated values in 2015 
have showed decreasing amounts which could be explained by a self-regulation of 
prescribers in front of the economic impact and practices changes. In 2014, eighty 
patients received defibrotide (mean: 19 years), main diagnosis was acute myelo-
blastic leukaemia. 90% of these patients who received defibrotide were attributed 
to the DRG corresponding to hematopoietic stem cell transplantation levels 3 or 4 
(tariff DRG cost: 51,725.20-71,948.73€ ). Portion of attributed to drugs (3,544-4,084€ ) 
cover a small part of treatment cost (97,524€ for an adult). Experts recommended 
harmonization of indications, improvement of pre-transplant cares (reduction of the 
liver damage and conditioning regimen intensity), optimization of vials numbers per 
patient (centralized preparations, limitation of treatment duration). cOnclusiOns: 
Aware of economic impact, experts have initiated a change of practice and they 
recommend a restrictive use of defibrotide specially limitation the off-label use in 
preventive (only patients with very high risk of VOD).
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Objectives: To Improve patient access toward new drugs, parallel MFDS(Ministry of 
Food and Drug Safety) and HIRA(Health Insurance Review and Assessment service) 
review processes have been introduced in South Korea since 2014. In parallel pro-
cesses, submission for reimbursement to HIRA is allowed during marketing authori-
zation process in MFDS. This study reports on evaluation of two years’ experiences 
and current issues. MethOds: We investigated reimbursement appraisal results of 
drugs submitted before their approval from 2014 to June 2015. The reduction of the 
length of time for patients’ access to new drug was calculated by the time between 
the submission to HIRA and authorization of MFDS. And extra budget impact of 
parallel processes was calculated. Results: Total six drugs were assessed for reim-
bursement upon parallel MFDA and HIRA processes. HIRA decided all six drugs to 
be reimbursed. The reduction of the length of time for patient access was average 
61 days in parallel processes comparing with the prior sequential process that sub-
mission for reimbursement was required to complete its marketing authorization 
process of MFDS. In case of two drugs of six reimbursed drugs, an estimated total 
drug cost expected to increase approximately three million USD per year compar-
ing with the estimated total drug cost assuming that if the 2 drugs were assessed 
in sequential review process. It resulted from the price of comparators of the two 
drugs scheduled to be discounted in the near future. Because of a patent expiration 
of the comparators, their price will be disounted after the listing date of the two 
new drugs. cOnclusiOns: Parallel MFDS and HIRA processes could contribute 
to patient access toward new drugs by 61 days earlier in South Korea. But in some 
drugs, it can be expected to change the budget compared with former sequential 
review process considering comparators’ patent expiration.
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Objectives: Advanced therapy medicinal products (ATMPs) are a class of innovative 
and regenerative therapies. As of May 2015, only 5 ATMPs were granted a market-
ing authorisation (MA) in European Union (EU): three cell therapies, Provenge® (for 
advanced prostate cancer), Chondrocelect® and MACI® (for cartilage defects); one 
tissue engineering product, Holoclar® (for damaged cornea); and one gene therapy, 
Glybera®(for lipoprotein lipase deficiency). The aim of this study was to review the 
ATMPs assessments by EU HTA bodies. MethOds: EU big 5 HTA body websites were 
searched for their decisions on ATMPs: France (HAS), UK (NICE, SMC), Italy (AIFA 
and regions), Spain (MSSSI and regions), Germany (IQWiG, G-BA). Grey literature was 
also searched for further details. Results: Chondrocelect® was only assessed in 
Spain and France; reimbursement was granted in Spain, rejected in France as effi-
cacy/adverse effects ratio had not been clearly established. Provenge® and MACI® 
were only assessed in the UK and Germany. NICE concluded that Provenge® did 
not demonstrate additional benefit nor cost-effectiveness against best supportive 
care; IQWiG/G-BA concluded “non-quantifiable” added benefit. MACI® was not rec-
ommended by NICE due to uncertainty in cost-effectiveness analysis and lack of 
long-term data, while its assessment has been suspended in Germany until further 
publication of randomised clinical trials. Only G-BA assessed Glybera® but could not 
conclude on its benefits due to limited data submitted by manufacturer. Holoclar® 
from which ATMPs could benefit to get early access. ATMPs may be the next source 
of major impact on payers’ drug budget.
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Objectives: The Affordable Care Act (ACA) has introduced several major changes 
which can impact product pricing, access and uptake in the United States. The 
objective of this analysis was to review all major new changes due to ACA and 
develop implications for market access for medical products. MethOds: The new 
pricing, access and coverage changes impacting the pharmaceutical and devices 
products were reviewed using the bill for ACA (H. R. 3590), 2011-2015 policy publica-
tions, reports by the Congressional Budget Office and Government Accountability 
Office, and the latest Centers for Medicare & Medicaid Services (CMS) guidelines 
for Essential Health Benefits (EHBs). Primary discussions with US private payers 
and ex-CMS policy experts were conducted to understand key issues for medical 
products. Results: The ACA has introduced major changes for product pricing, 
deductible, coverage and uptake. For pricing, major changes are a 50% discount for 
Part D population and an increased rebate of 23.1% for the Medicaid population. 
For deductibles, the patient costs are capped at $12,700. For uptake, an additional 
population is eligible based on expanded access to 30 million uninsured Americans, 
with more than half of them being under the age of 35 years (~59%). For access, 
the 2014 definition of Essential Drug Benefits is likely to either expand or reduce 
coverage depending upon the state and class of drugs. For example, for NSAIDs 
in CA only 20 drugs are covered, while in NY, 40 drugs are covered. During 2012-
2014 Accountable Care Organizations (ACOs) have increased to ~600 organizations 
covering ~18 million lives, which has created a new stakeholder of an integrated 
provider-payer partnership. cOnclusiOns: ACA has introduced major changes 
which will have a significant impact on converge, pricing and access of pharma-
ceutical and device products.
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Objectives: Turkey applies molecule-based equivalence grouping and Social 
Security Institution (SGK), the sole public payer of pharmaceuticals, pays a cap 
which is at most 10% over the lowest (base) price of each group. As of October 1 
2014, SGK lowered the cap to base price for selected 15 groups. The objective of 
this study is to analyze the preliminary impact of this policy change and compute 
whether it provides necessary saving and price reduction. MethOds: Claims data 
from SGK for all drugs included in the selected groups were collected monthly for 
June and July 2014, denoted as pre-policy change period; October and November 
2014, defined as post-policy change period. Price changes, saving impact, patient 
contribution rate, and utilization rates were compared and analyzed. Results: 
Among 212 drugs in those groups, the price of 180 drugs stayed the same whereas 6 
increased and 26 decreased. With this policy shift, SGK generated a saving of nearly 
10%; base price, prescription substitution, and price erosion impacts contributed 
by 7, 1, and 2 percentage points respectively. Besides, cost per unit, weighted aver-
age of total sales value divided by total sales volume, reduced by 9% compared 
to pre-policy change period. Base-priced drugs’ sales volume (value) climbed by 
3 (6) percentage points. Although it was estimated that patient contribution rate 
would rise by 8 percentage points on average after the new policy, in reality it 
reached 18% with an increase of 5 percentage points, thanks to price reduction 
due to competition and higher utilization of base-priced drugs. cOnclusiOns: 
Based on primary data, it seems the new policy provided the desired effect on 
price reduction and utilization increase of base-priced drugs, hence saving with 
minor impact on patient contribution.
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Objectives: Following the availability of biosimilars of Remicade (infliximab, 
Janssen Cilag) - which target severe pathologies - a national tender was launched 
in Norway in order to negotiate discounts. Orion, manufacturing the biosimilar 
Remsima, won the national tender by offering a 72% discount compared with 
Remicade in February 2015. Hospira, manufacturing the biosimilar Inflectra, offered 
a 51% discounts. Given the extent of the discounts and wide publicity of the prices, 
the goal of this survey was to assess if list prices of infliximab were impacted in 
Norway as well as in countries using Norway in their International Reference Pricing 
(IRP) rules. MethOds: Ex-manufacturer list price changes over time for Remicade 
and biosimilars of infliximab were analysed in Norway as well as in countries using 
Norway in their IRP rules and for which list prices are available, namely: Denmark, 
Finland, Iceland, Poland and Slovenia. Results: Our results show that while the 
tender led to significant discounts, list prices (since biosimilars are available) of 
either the biologic product or biosimilars have remained constant in Norway. 
Additionally, prices have remained constant in all countries using Norway in their 
IRP rules except for Iceland, where prices have regularly decreased. The change is 
however not linked to IRP rules. cOnclusiOns: The research indicates that prices 
around the world for Remicade and infliximab biosimilars have not been impacted 
by price changes in Norway. Whilst the new prices generated significant global 
attention, they have not been formally incorporated into pricing negotiations else-
where, at least for the time being. This is partly because certain countries may not 
